top of page
The Professional Network for Healthcare Experts
Zealand Pharma licenses GLP-1/gastrin peptide platform to Elvinix for type 1 diabetes
Zealand Pharma has licensed its GLP-1/gastrin dual-agonist peptide platform to Elvinix for development as a potentially regenerative treatment for type 1 diabetes.
nuaxia
1 day ago2 min read
Aizen Therapeutics signs AI peptide collaboration worth up to $100 million per target
The multi-program deal pairs Aizen’s DaX AI platform with an undisclosed San Diego biotechnology company to design oral peptide therapeutics against nominated immunology and neurology targets.
nuaxia
Aug 173 min read
bottom of page